Yaprak Donmez Cakil
ID
Zeynep Gunes Ozunal
ID
 Email src
Damla Gokceoglu Kayali
ID
Ranan Gulhan Aktas
ID
Department of Histology and Embryology, Faculty of Medicine, Maltepe University, Istanbul, Turkey
Cancer and Stem Cell Research Center, Faculty of Medicine, Maltepe University, Istanbul, Turkey
Cancer and Stem Cell Research Center, Faculty of Medicine, Maltepe University, Istanbul, Turkey
Department of Histology and Embryology, Faculty of Medicine, Maltepe University, Istanbul, Turkey
Received: 23 November 2020 / Accepted: 14 December 2020 / Published: 30 March 2021

Abstract

Introduction. Cancer is a leading cause of mortality. Hepatocellular cancer is one of the malignancies associated with poor outcome and resistance to pharmacotherapy. Cancer stem cells (CSCs) contribute to resistance to therapy and hence lead to the treatment failure of tumors.

Aim. This study aims to explore the expression of CSCs in response to cisplatin treatment in HepG2 hepatocellular cancer cell line.

Material and methods. Cell proliferation test, CCK-8, was used to evaluate the cell proliferation following cisplatin treatment for 72 hours. The expressions of CSC markers CD44, CD90, and CD133 were assessed by flow cytometric analysis.

Results. The results showed a dose-dependent decrease in cell proliferation and increased expression of CSC markers CD44 and CD90 in response to cisplatin.

Conclusion. Understanding the roles of CSC markers may point to new targets and therapeutic strategies to predict and overcome cisplatin resistance.

 

Cite

Domnez Cakıl Y, Ozunal ZG, Kayalı DG, Aktas RG. The expression of CD44, CD90 and CD133 in response to cisplatin in hepatocellular cancer cells. Eur J Clin Exp Med. 2021;19(1):18–22. doi: 10.15584/ejcem.2021.1.3

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited